NASDAQ:MNOV MediciNova (MNOV) Stock Forecast, Price & News $2.10 -0.03 (-1.41%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.07▼$2.1050-Day Range$2.01▼$2.5152-Week Range$1.89▼$2.73Volume23,225 shsAverage Volume18,893 shsMarket Capitalization$103.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MediciNova MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish0.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.33) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.61 out of 5 starsMedical Sector962nd out of 963 stocksPharmaceutical Preparations Industry449th out of 450 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MediciNova. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.79% of the float of MediciNova has been sold short.Short Interest Ratio / Days to CoverMediciNova has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.Change versus previous monthShort interest in MediciNova has recently increased by 0.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMediciNova does not currently pay a dividend.Dividend GrowthMediciNova does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNOV. Previous Next 1.8 News and Social Media Coverage News SentimentMediciNova has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MediciNova this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added MediciNova to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediciNova insiders have not sold or bought any company stock.Percentage Held by Insiders16.90% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.97% of the stock of MediciNova is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediciNova are expected to decrease in the coming year, from ($0.33) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediciNova is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediciNova is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediciNova has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MediciNova (NASDAQ:MNOV) StockMediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Read More MNOV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNOV Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.comSeptember 26, 2023 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Stock Price Passes Above 200 Day Moving Average of $2.25September 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 18, 2023 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.comAugust 21, 2023 | finance.yahoo.comMNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury…August 17, 2023 | finance.yahoo.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-OncologyAugust 16, 2023 | benzinga.comMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in EuropeAugust 16, 2023 | finance.yahoo.comMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in EuropeSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 16, 2023 | msn.comMedicinova (NASDAQ:MNOV) Rises on Key Patent Win in EuropeAugust 15, 2023 | finance.yahoo.comMediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in EuropeAugust 14, 2023 | finance.yahoo.comMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in EuropeJuly 23, 2023 | finance.yahoo.comWith 49% ownership, MediciNova, Inc. (NASDAQ:MNOV) has piqued the interest of institutional investorsJune 29, 2023 | msn.comTraders Cheer After Bank Stress Test Results, Lifting US Equity FuturesJune 29, 2023 | finance.yahoo.comMediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific MeetingMay 30, 2023 | finance.yahoo.comMNOV: Compelling Buying Opportunity in Differentiated Small-Cap BiotechMay 15, 2023 | finance.yahoo.comMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in EuropeMay 14, 2023 | finance.yahoo.comMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in EuropeApril 30, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in CanadaApril 15, 2023 | finance.yahoo.comMediciNova, Inc. (MNOV) Stock Historical Prices & Data - Yahoo FinanceMarch 31, 2023 | nasdaq.comMedicinova Inc Common Stock (MNOV)March 9, 2023 | finance.yahoo.comMediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryFebruary 27, 2023 | finance.yahoo.comMNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…February 20, 2023 | finance.yahoo.comMediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and TherapeuticsFebruary 8, 2023 | finance.yahoo.comMediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVIDJanuary 30, 2023 | finance.yahoo.comMediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use DisorderJanuary 12, 2023 | finance.yahoo.comMediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed GlioblastomaSee More Headlines Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address MNOV Company Calendar Last Earnings8/09/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees13Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.02% Return on Assets-17.02% Debt Debt-to-Equity RatioN/A Current Ratio18.97 Quick Ratio18.97 Sales & Book Value Annual Sales$4.04 million Price / Sales25.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book1.47Miscellaneous Outstanding Shares49,046,000Free Float40,757,000Market Cap$103.00 million OptionableOptionable Beta0.93 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Yuichi Iwaki M.D. (Age 73)Ph.D., Co-Founder, Pres, CEO & Exec. Director Comp: $933.05kDr. Kazuko Matsuda M.D. (Age 57)M.P.H., MPH, Ph.D., Chief Medical Officer & Director Comp: $653.65kMr. Jason J. Kruger CPA (Age 46)CFO & Principal Financial Officer Dr. David H. Crean M.B.A. (Age 58)Ph.D., Chief Bus. Officer Mr. John O'Neil CPAControllerKey CompetitorsCitius PharmaceuticalsNASDAQ:CTXRI-MabNASDAQ:IMABAquestive TherapeuticsNASDAQ:AQSTAnixa BiosciencesNASDAQ:ANIXMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 1,300 shares on 8/15/2023Ownership: 0.000%Ergoteles LLCSold 38,123 shares on 8/14/2023Ownership: 0.063%BlackRock Inc.Bought 16,488 shares on 8/11/2023Ownership: 1.491%JPMorgan Chase & Co.Sold 8,164 shares on 8/11/2023Ownership: 0.343%Citigroup Inc.Bought 50,300 shares on 8/10/2023Ownership: 1.016%View All Insider TransactionsView All Institutional Transactions MNOV Stock - Frequently Asked Questions Should I buy or sell MediciNova stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNOV shares. View MNOV analyst ratings or view top-rated stocks. How have MNOV shares performed in 2023? MediciNova's stock was trading at $2.05 at the start of the year. Since then, MNOV stock has increased by 2.4% and is now trading at $2.10. View the best growth stocks for 2023 here. When is MediciNova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our MNOV earnings forecast. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY). What is MediciNova's stock symbol? MediciNova trades on the NASDAQ under the ticker symbol "MNOV." Who are MediciNova's major shareholders? MediciNova's stock is owned by a number of institutional and retail investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (38.02%), BlackRock Inc. (1.49%), Citigroup Inc. (1.02%), JPMorgan Chase & Co. (0.34%), Bank of Montreal Can (0.26%) and Dimensional Fund Advisors LP (0.23%). View institutional ownership trends. How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MediciNova's stock price today? One share of MNOV stock can currently be purchased for approximately $2.10. How much money does MediciNova make? MediciNova (NASDAQ:MNOV) has a market capitalization of $103.00 million and generates $4.04 million in revenue each year. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. How can I contact MediciNova? MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048. This page (NASDAQ:MNOV) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.